Swiss Banks Stock News

Why ARYZTA’s 2026 outlook is in focus ARYZTA (SWX:ARYN) updated investors during its 2025 sales and trading statement call on 22 January 2026, pairing the update with fresh 2026 guidance that indicates revenue growth and improved performance. See our latest analysis for ARYZTA. ARYZTA’s latest 2026 guidance appears to have acted as a fresh catalyst, with a 7-day share price return of 9.4% and a 1-month share price return of 6.0%. This comes even though the 1-year total shareholder return is a...

Cain & Bultman partnership puts Sika (SWX:SIKA) distribution in focus Sika (SWX:SIKA) is in the spotlight after Cain & Bultman agreed to distribute its floor covering installation products through commercial and residential dealers across several southeastern U.S. states, widening the company’s reach in that region. See our latest analysis for Sika. Sika’s CHF147.45 share price sits against a year to date share price return of 9.93% and a 1 year total shareholder return of 35.59% decline,...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Shareholders in HIAG Immobilien Holding AG ( VTX:HIAG ) may be thrilled to learn that the analysts have just delivered...

Key Insights Emmi's estimated fair value is CHF1,487 based on 2 Stage Free Cash Flow to Equity Emmi is estimated to be...

As an investor, mistakes are inevitable. But you want to avoid the really big losses like the plague. So take a moment...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Siegfried Holding AG ( VTX:SFZN ) shares have had a really impressive month, gaining 35% after a shaky period...

Galenica (SWX:GALE) has drawn fresh attention after reporting 2025 group sales of CHF 4,135.6 million, reaffirming dividend guidance, and confirming EBIT is expected to rise 10 to 12% following the Labor Team acquisition. See our latest analysis for Galenica. Those full year sales and earnings updates have arrived alongside a CHF97.25 share price, with a 15.16% 90 day share price return and a 23.46% 1 year total shareholder return suggesting momentum has strengthened recently. If you are...

INFICON Holding (SWX:IFCN) issued preliminary 2025 guidance that points to sales of about US$673.7 million and operating income of roughly US$112.3 million, indicating stable revenue but softer profitability expectations. See our latest analysis for INFICON Holding. The share price reaction to INFICON Holding's guidance has come on top of strong recent momentum, with a 31.84% 1 month share price return and a 38.92% 3 month share price return. The 1 year total shareholder return of 14.85% and...

In January 2026, VAT Group AG reported preliminary results showing fourth-quarter 2025 net sales of CHF 257 million, down from CHF 283.2 million a year earlier, while full-year 2025 net sales rose to CHF 1,073 million from CHF 942.2 million. An interesting detail is that preliminary fourth-quarter orders climbed to about CHF 305 million, growing both sequentially and year on year, even though full-year 2025 orders stayed roughly flat at around CHF 1,033 million. We will now examine how the...

If you have been wondering whether UBS Group at about CHF37.31 is priced attractively or already reflects a lot of good news, you are not alone. The stock has been fairly steady in the short term, with a 0.5% decline over the last 7 days and a 1.0% gain over the past month, while the 1 year return sits at 20.9% and the 3 year return is 104.5%, with a very large 5 year return of 226.6%. Recent months for UBS Group have featured ongoing integration work and balance sheet repositioning...

Formula E and Google Cloud have entered a multi year AI partnership for the ABB FIA Formula E World Championship. Google Cloud becomes the Principal Artificial Intelligence Partner, providing tools such as digital twins and AI modeling for race operations and sustainability objectives. The agreement links ABB more closely with advanced data and AI use cases in next generation motorsport and electrification. For ABB (SWX:ABBN), this new AI focused partnership around the ABB FIA Formula E...

If you are wondering whether Roche Holding at CHF350.50 still offers value or if most of the upside is already priced in, you are in the right place. The stock has returned 1.1% over the last 7 days, 6.3% over 30 days, 7.7% year to date, 29.6% over 1 year, 35.7% over 3 years, and 32.7% over 5 years, which gives useful context before weighing up what you are paying today. Recent news around Roche has focused on its position in global pharmaceuticals and ongoing developments across its key...

Generally speaking long term investing is the way to go. But unfortunately, some companies simply don't succeed. To...

Swiss Life Holding AG recently presented at Citi's European Insurance Conference 2026 in London, offering investors fresh commentary from the insurer’s leadership on the sector and its positioning. This high-profile forum can give the market clearer visibility into management priorities and capital allocation thinking, potentially reshaping how Swiss Life’s long-term story is understood. We’ll now explore how Swiss Life’s appearance at Citi’s European Insurance Conference may influence its...

In January 2026, Implenia announced it had secured around €350 million of new bridge and tunnel contracts in Germany and Norway, covering major motorway links such as the Peene bridge at Wolgast, the Markbreit bridge on the A7 corridor, and the Riederwald tunnel in Frankfurt. These technically complex, long-duration projects underline Implenia’s focus on large-scale mobility infrastructure and expand its role in critical European transport corridors that support freight, tourism and regional...

PolyPeptide Group AG recently reported preliminary 2025 figures pointing to about €389 million in revenue and an EBITDA margin of 11.0%–12.0%, supported by demand for metabolic therapeutics and ongoing capital spending. This early look at revenue and profitability offers investors an insight into how exposure to metabolic therapies may be reshaping PolyPeptide’s business mix ahead of its full audited 2025 results on 12 March 2026. Next, we’ll explore how this improved EBITDA margin guidance...

Galenica AG reported that group sales for the year ended December 2025 rose to CHF 4,135.6 million from CHF 3,921.1 million, while confirming higher EBIT guidance linked to the Labor Team acquisition and indicating the 2025 dividend should be at least in line with the prior year. This combination of stronger sales, an improved earnings outlook and maintained dividend expectations highlights how Galenica is integrating acquisitions while supporting shareholder returns. We will now examine how...

In January 2026, Geberit AG reported its full-year 2025 results, with currency-adjusted net sales up 4.8% and Swiss franc net sales rising 2.5% to CHF 3,163 million, clearly outpacing overall market development. This performance indicates that Geberit gained ground against competitors, as its sales growth meaningfully exceeded the broader market’s expansion in 2025. We will now examine how Geberit’s above-market 4.8% currency-adjusted sales growth shapes its investment narrative and future...

HIAG Immobilien Holding (SWX:HIAG) has drawn attention after guiding for 2025 consolidated net profit to be 50% to 55% above the 2024 figure of CHF 75.2 million, indicating a marked uplift versus prior expectations. See our latest analysis for HIAG Immobilien Holding. The stronger 2025 earnings guidance has arrived after a solid run in the share price, with a 90 day share price return of 12.55% and a 1 year total shareholder return of 48.09%, suggesting momentum has been building rather than...

Earlier this year, Partners Group CEO David Layton said private markets should be a core part of balanced portfolios, highlighting that the firm has raised US$9.40 billion from private wealth clients and expanded its custom account business to US$66.00 billion amid demand for bespoke solutions. Layton also pointed out that private market valuations sit below prior peak levels, suggesting investors may find current conditions comparatively attractive for allocating to alternatives within a...

Idorsia Ltd. recently reported in Nature Communications the Phase 3 MODIFY and open-label extension results for lucerastat, an oral substrate reduction therapy in adults with Fabry disease, which did not meet its primary neuropathic pain endpoint but showed sustained biomarker reductions and encouraging renal outcomes. The data, including a slower rate of eGFR decline and stabilization of cardiac measures in patients with impaired kidney function, have guided the design of a new Phase 3...

On 23 January 2026, Kuros Biosciences drew heightened investor attention as trading activity increased ahead of its 10 March 2026 earnings release and anticipated clinical updates in orthobiologics. The focus on MagnetOs and the fibrin/PTH spinal fusion and fracture programs highlights how upcoming medical data milestones may influence perceptions of the company’s pipeline progress. With a recent 7-day gain and interest in its fibrin/PTH program, we’ll examine how these developments shape...